236 related articles for article (PubMed ID: 36140541)
1. Current Status of
Hadebe B; Sathekge MM; Aldous C; Vorster M
Diagnostics (Basel); 2022 Sep; 12(9):. PubMed ID: 36140541
[TBL] [Abstract][Full Text] [Related]
2. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.
Osl T; Schmidt A; Schwaiger M; Schottelius M; Wester HJ
Theranostics; 2020; 10(18):8264-8280. PubMed ID: 32724470
[TBL] [Abstract][Full Text] [Related]
3. Nuclear Medicine Application of Pentixafor/Pentixather Targeting CXCR4 for Imaging and Therapy in Related Disease.
Chen Z; Xue Q; Yao S
Mini Rev Med Chem; 2023; 23(7):787-803. PubMed ID: 36529918
[TBL] [Abstract][Full Text] [Related]
4. [
Lapa C; Schreder M; Schirbel A; Samnick S; Kortüm KM; Herrmann K; Kropf S; Einsele H; Buck AK; Wester HJ; Knop S; Lückerath K
Theranostics; 2017; 7(1):205-212. PubMed ID: 28042328
[TBL] [Abstract][Full Text] [Related]
5. Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients.
Bluemel C; Hahner S; Heinze B; Fassnacht M; Kroiss M; Bley TA; Wester HJ; Kropf S; Lapa C; Schirbel A; Buck AK; Herrmann K
Clin Nucl Med; 2017 Jan; 42(1):e29-e34. PubMed ID: 27819856
[TBL] [Abstract][Full Text] [Related]
6. CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [
Jacobs SM; Wesseling P; de Keizer B; Tolboom N; Ververs FFT; Krijger GC; Westerman BA; Snijders TJ; Robe PA; van der Kolk AG
Eur J Nucl Med Mol Imaging; 2022 Jan; 49(2):481-491. PubMed ID: 33550492
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic efficacy of C-X-C motif chemokine receptor 4-directed PET/CT in newly diagnosed head and neck squamous cell carcinoma - a head-to-head comparison with [
Zhi Y; Werner RA; Schirbel A; Higuchi T; Buck AK; Kosmala A; Bley TA; Hagen R; Hackenberg S; Rosenwald A; Scherzad A; Gerhard-Hartmann E; Serfling SE
Am J Nucl Med Mol Imaging; 2023; 13(5):208-216. PubMed ID: 38023816
[TBL] [Abstract][Full Text] [Related]
8. Imaging Inflammation in Atherosclerosis with CXCR4-Directed
Kircher M; Tran-Gia J; Kemmer L; Zhang X; Schirbel A; Werner RA; Buck AK; Wester HJ; Hacker M; Lapa C; Li X
J Nucl Med; 2020 May; 61(5):751-756. PubMed ID: 31653710
[TBL] [Abstract][Full Text] [Related]
9. Investigation of spleen CXCR4 expression by [
Lewis R; Habringer S; Kircher M; Hefter M; Peuker CA; Werner R; Ademaj-Kospiri V; Gäble A; Weber W; Wester HJ; Buck A; Herhaus P; Lapa C; Keller U
EJNMMI Res; 2021 Aug; 11(1):77. PubMed ID: 34417915
[TBL] [Abstract][Full Text] [Related]
10. Response assessment with the CXCR4-directed positron emission tomography tracer [
Herhaus P; Habringer S; Vag T; Steiger K; Slotta-Huspenina J; Gerngroß C; Wiestler B; Wester HJ; Schwaiger M; Keller U
EJNMMI Res; 2017 Dec; 7(1):51. PubMed ID: 28577295
[TBL] [Abstract][Full Text] [Related]
11. CXCR4-Directed Imaging in Solid Tumors.
Werner RA; Kircher S; Higuchi T; Kircher M; Schirbel A; Wester HJ; Buck AK; Pomper MG; Rowe SP; Lapa C
Front Oncol; 2019; 9():770. PubMed ID: 31475113
[TBL] [Abstract][Full Text] [Related]
12. (68)Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma.
Lapa C; Lückerath K; Kleinlein I; Monoranu CM; Linsenmann T; Kessler AF; Rudelius M; Kropf S; Buck AK; Ernestus RI; Wester HJ; Löhr M; Herrmann K
Theranostics; 2016; 6(3):428-34. PubMed ID: 26909116
[TBL] [Abstract][Full Text] [Related]
13. Pentixafor PET/CT for imaging of chemokine receptor 4 expression in esophageal cancer - a first clinical approach.
Linde P; Baues C; Wegen S; Trommer M; Quaas A; Rosenbrock J; Celik E; Marnitz S; Bruns CJ; Fischer T; Schomaecker K; Wester HJ; Drzezga A; van Heek L; Kobe C
Cancer Imaging; 2021 Feb; 21(1):22. PubMed ID: 33579381
[TBL] [Abstract][Full Text] [Related]
14. CXCR4-Directed PET/CT with [
Chen Z; Yang A; Zhang J; Chen A; Zhang Y; Huang C; Chen S; Yao S; Miao W
Mol Imaging Biol; 2022 Jun; 24(3):416-424. PubMed ID: 34651291
[TBL] [Abstract][Full Text] [Related]
15. Targeting CXCR4 with [
Lapa C; Kircher S; Schirbel A; Rosenwald A; Kropf S; Pelzer T; Walles T; Buck AK; Weber WA; Wester HJ; Herrmann K; Lückerath K
Oncotarget; 2017 Nov; 8(57):96732-96737. PubMed ID: 29228566
[TBL] [Abstract][Full Text] [Related]
16. Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach.
Werner RA; Weich A; Higuchi T; Schmid JS; Schirbel A; Lassmann M; Wild V; Rudelius M; Kudlich T; Herrmann K; Scheurlen M; Buck AK; Kropf S; Wester HJ; Lapa C
Theranostics; 2017; 7(6):1489-1498. PubMed ID: 28529632
[TBL] [Abstract][Full Text] [Related]
17.
Kraus S; Dierks A; Rasche L; Kertels O; Kircher M; Schirbel A; Zovko J; Steinbrunn T; Tibes R; Wester HJ; Buck AK; Einsele H; Kortüm KM; Rosenwald A; Lapa C
J Nucl Med; 2022 Jan; 63(1):96-99. PubMed ID: 34049979
[TBL] [Abstract][Full Text] [Related]
18. First
Poschenrieder A; Osl T; Schottelius M; Hoffmann F; Wirtz M; Schwaiger M; Wester HJ
Tomography; 2016 Jun; 2(2):85-93. PubMed ID: 30042959
[TBL] [Abstract][Full Text] [Related]
19. PET imaging of chemokine receptor CXCR4 in patients with primary and recurrent breast carcinoma.
Vag T; Steiger K; Rossmann A; Keller U; Noske A; Herhaus P; Ettl J; Niemeyer M; Wester HJ; Schwaiger M
EJNMMI Res; 2018 Sep; 8(1):90. PubMed ID: 30191351
[TBL] [Abstract][Full Text] [Related]
20. [
Schwarzenböck SM; Stenzel J; Otto T; Helldorff HV; Bergner C; Kurth J; Polei S; Lindner T; Rauer R; Hohn A; Hakenberg OW; Wester HJ; Vollmar B; Krause BJ
Oncotarget; 2017 Nov; 8(56):95606-95619. PubMed ID: 29221153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]